Drug | Parameter | Fold Induction | Fold Increase | ||||
---|---|---|---|---|---|---|---|
HC3-15 | HC1-18/HC3-17a | HC5-10 | HC3-15 | HC1-18/HC3-17a | HC5-10 | ||
ASV | Emax | 14.21 | 6.74 | 3.94 | 14.10 | 6.68 | 3.00 |
EC50 (µg/ml) | 1.00 | 0.61 | 0.58 | 1.38 | 0.68 | 0.78 | |
DCV | Emax | 28.24 | 13.05 | 8.27 | 45.30 | 11.90 | 12.80 |
EC50 (µg/ml) | 4.32 | 1.83 | 2.38 | 7.64 | 1.96 | 6.54 | |
BCV | Emax | 6.54 | 2.36 | 2.44 | 6.17 | 2.23 | 1.64 |
EC50 (µg/ml) | 0.20 | 0.03 | 0.02 | 0.46 | 0.45 | 0.19 | |
BCV-M1 | Emax | 9.68 | 2.30 | 2.74 | 9.13 | 1.55 | 1.62 |
EC50 (µg/ml) | 0.39 | 0.02 | 0.21 | 0.58 | 0.19 | 0.47 |
↵a Induction of ASV and DCV was evaluated using lot HC1-18 hepatocytes; induction of BCV and BCV-M1 was evaluated using lot HC3-17 hepatocytes.